American Society of Clinical Oncology
225 Reinekers Lane
Suite 650
Alexandria
Virginia
22314
United States
Tel: 703-299-0150
Fax: 703-299-1044
Website: http://www.asco.org/
Email: asco@asco.org
2076 articles with American Society of Clinical Oncology
-
Anpac Bio Presenting 'Unprecedented' Cerebral Cancer Liquid Biopsy Research Results at ASCO 2019
5/30/2019
International life sciences corporation announced the company is presenting "unprecedented" cerebral cancer research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 31 – June 4, 2019.
-
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
-
Medidata to Present Breakthrough Innovation at 2019 ASCO Annual Meeting
5/24/2019
How data and technology enable more patients to receive the most promising new experimental therapies during a clinical trial - a collaboration with Friends of Cancer Research
-
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting
5/24/2019
Ipsen announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib, liposomal irinotecan, and lanreotide autogel will be presented at the 2019 American Society of Clinical Oncology Annual Meeting.
-
Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers
5/23/2019
Ascentage Pharma announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
-
Genomic Testing Cooperative (GTC) and Collaborators to Present Data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting
5/22/2019
Genomic Testing Cooperative, LCA announced that data using its unique DNA and RNA profiling will be presented at the American Society of Clinical Oncology annual meeting.
-
Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML)
5/20/2019
Novel Genomic Biomarker of Response to Enzastaurin in Glioblastoma Identified
-
Lan Huang, chief executive officer of BeyondSpring, believes her company has the “secret sauce” that could provide beneficial treatment to chemotherapy-induced neutropenia, a common side effect for chemotherapy patients.
-
Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.
-
Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting
5/16/2019
Flatiron Health announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago.
-
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
5/16/2019
Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options
-
Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019
5/16/2019
Intensity Therapeutics, Inc. announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2019 in Chicago.
-
Fusion Pharmaceuticals Announces Poster Presentation at ASCO 2019
5/16/2019
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced that it will present a poster at the 2019 American Society of Clinical Oncology meeting, which is being held from May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois.
-
Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings
5/16/2019
Epizyme, Inc. announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June.
-
Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO
5/16/2019
Alligator Bioscience, announces that Janssen Biotech, Inc. will present data from a Phase I clinical study of ADC-1013 at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4.
-
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
5/16/2019
Novartis will present data from across its oncology portfolio at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology, taking place May 31-June 4 in Chicago; and the 24th Annual Congress of the European Hematology Association, scheduled for June 13-16 in Amsterdam.
-
H3 Biomedicine to Present Data from Two Ongoing Precision Medicine Clinical Programs at 2019 ASCO Annual Meeting
5/16/2019
H3 Biomedicine Inc., a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., announced it will present four posters during the 2019 American Society of Clinical Oncology Annual Meeting, which will be held May 31 – June 4, 2019 in Chicago.
-
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
5/16/2019
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
-
AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting
5/16/2019
AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA® and IMFINZI® at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 to June 4, 2019.
-
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
5/16/2019
New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months